Likewise, these data indicate that SEMA3F/NRP1/NRP2 could be considered new therapeutic targets and relevant poor prognostic biomarkers for patient clinical management and outcomes in DCIS lesions (Fig. 8). Here, SEMA3F is linked to ductal breast carcinoma in situ.